The objective was to evaluate the efficacy and safety of recombinant activated factor VII in patients with massive bleeding. Forty-five patients with severe massive hemorrhage requiring= 14 transfusion units of packed red blood cells received recombinant activated factor VII. Postdrug blood loss and transfusion requirements were assessed, and mortality was compared with predicted outcomes. Blood loss was markedly reduced in 40 of 43 (93.0%) patients, and transfusion requirements decreased after recombinant activated factor VII administration. Mortality rate in trauma patients who had massive hemorrhage was significantly reduced compared with predictions using scoring systems. This may be associated with the use of recombinant activated factor VII. This study failed to demonstrate an improvement in surgical patients. The absence of concurrent controls prevents definitive conclusions regarding actual safety or efficacy of recombinant activated factor VII.
Ferrara A, MacArthur JD, Wright HK, Modlin IM, McMillen MA. Hypothermia and acidosis worsen coagulopathy in the patient requiring massive transfusion. Am J Surg. 1990;160:515-518.
2.
Williamson LM, Lowe S, Love EM, et al. Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. BMJ.1999;319:16-19.
3.
Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma.2001;51:431-439.
4.
Claridge JA, Sawyer RG, Schulman AM, McLemore EC, Young JS. Blood transfusions correlate with infections in trauma patients in a dose-dependent manner. Am Surg. 2002;68:566-572.
5.
Hill GE, Frawley WH, Griffith KE, Forestner JE, Minei JP. Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. J Trauma.2003;54:908-914.
6.
Sawyer PR, Harrison CR. Massive transfusion in adults. Diagnoses, survival and blood bank support. Vox Sang.1990;58:199-203.
7.
Harvey MP, Greenfield TP, Sugrue ME, Rosenfeld D. Massive blood transfusion in a tertiary referral hospital. Clinical outcomes and haemostatic complications. Med J Aust.1995;163:356-359.
8.
Davies MJ, Allen A, Kort H, et al. Prospective, randomized, double-blind study of high-dose aprotinin in pediatric cardiac operations. Ann Thorac Surg.1997;63:497-503.
9.
Llamas P, Cabrera R, Gomez-Arnau J, Fernandez MN. Hemostasis and blood requirements in orthotopic liver transplantation with and without high-dose aprotinin. Haematologica.1998;83:338-346.
10.
Dunn CJ, Goa KL. Fibrin sealant: a review of its use in surgery and endoscopy. Drugs.1999;58:863-886.
11.
Carless PA, Anthony DM, Henry DA. Systematic review of the use of fibrin sealant to minimize perioperative allogeneic blood transfusion. Br J Surg.2002;89:695-703.
12.
Flati G, Andren-Sandberg A, La Pinta M, Porowska B, Carboni M. Potentially fatal bleeding in acute pancreatitis: pathophysiology, prevention, and treatment. Pancreas. 2003;26:8-14.
13.
Hedner U.NovoSeven as a universal haemostatic agent. Blood Coagul Fibrinolysis.2000;11(suppl 1):S107-S111.
14.
Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet. 2003;361:201-205.
15.
Lodge JP, Jonas S, Oussoultzoglou E, et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology.2005;102:269-275.
16.
Lodge JPA, Jonas S, Jones RM, et al. Efficacy and safety of repeated peri-operative doses of recombinant factor VIIa in liver transplantation. Liver Transplant.2005;11:973-979.
17.
Raobaikady R, Redman J, Ball JA, Maloney G, Grounds RM. Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a doubleblind, randomized, placebo-controlled trial. Br J Anaesth. 2005;94:586-591.
18.
Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel, randomized placebo-controlled, double-blind clinical trials. J Trauma.2005;59:8-18.
19.
Baker SP, O'Neill B, Haddon W Jr, Long WB. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma. 1974;14:187-196.
20.
Boyd CR, Tolson MA, Copes WS. Evaluating trauma care: the TRISS method. Trauma Score and the Injury Severity Score. J Trauma.1987;27:370-378.
21.
Champion HR, Sacco WJ, Copes WS, et al. A revision of the Trauma Score. J Trauma.1989;29:623-629.
Copeland GP, Jones D, Walters M. POSSUM: a scoring system for surgical audit. Br J Surg.1991;78:355-360.
24.
Prytherch DR, Whiteley MS, Higgins B, et al. POSSUM and Portsmouth POSSUM for predicting mortality. Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity. Br J Surg.1998;85:1217-1220.
25.
Hoffman M, Monroe DM III, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis. 1998;9(suppl 1):S61-S65.
26.
Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol.1997;99:542-547.
27.
White B, McHale J, Ravi N. Successful use of recombinant FVIIa in the management of post-surgical intra-abdominal haemorrhage. Br J Haematol.1999;107:677-678.
28.
Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999;354:1879-1879.
29.
Kristensen J, Killander A, Hippe E, et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis.1996;26(suppl 1):159-164.
30.
Clark AD, Gordon WC, Walker ID, Tait RC. “Last-ditch” use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang.2004;86:120-124.
31.
Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology. 2004;127:1123-1130.
32.
Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med.2005;352:777-785.
33.
Bernstein D, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIA corrects prothombin time in cirrhotic patients: a preliminary study. Gastroenterology.1997;113:1930-1937.
34.
Ejlersen E, Melsen T, Ingerslev J, Andresen R, Vilstrup H. Recombinant activated factor VIIa (rFVIIa) acutly normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol.2001;36:1081-1085.
35.
McIlroy B, Millar A, Copeland GP, Kiff R. Audit of emergency preoperative resuscitation. Br J Surg.1994;81:200-202.
